ClinicalTrials.gg
CompletedNCT03038646Updated Aug 31, 2017

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

A Phase 1 interventional study of MIN-101 in Healthy Subjects, sponsored by Minerva Neurosciences. Completed at 1 site in Ireland. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-08-31.

Sponsored by Minerva Neurosciences · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

  • To evaluate the pharmacokinetic (PK) profiles of MIN-l0l following administration of modified release (MR) formulations of MIN-l0l in healthy male and female subjects
  • To select 1 MR formulation for use in fed state
  • To evaluate the effect of food on the bioavailability of MIN-l0l selected MR formulation
02

Conditions studied

  • Healthy Subjects

Keywords

  • Pharmacokinetics
  • Food Effect
03

In context

Lead sponsor

Minerva Neurosciences is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed CYP 2D6 extensive metaboliser genotype
  2. Subject has given voluntary written before performance of any study related procedure
  3. Must be 18 to 45 years of age, inclusive
  4. Subject must be a healthy male or female as indicated by the protocol
  5. Agree to abstain from all medication (except for allowed for 21 days before the first dose with MIN-101
  6. Subject agrees to use the methods of birth control as outlined in the protocol
  7. Must be willing and able to communicate and participate in the whole study.
  8. Willing to eat all the food supplied throughout the study.

Exclusion criteria

Exclusion Criteria:

  1. A history of gastrointestinal disease, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic or psychiatric disease or any other condition which, in the opinion of the principle investigator, would jeopardize the safety of the subject or impact the validity of the study results
  2. Acute diarrhoea or constipation in the 7 days before the predicted first study day.
  3. Subject has donated blood within 90 days or plasma within 30 days of study dosing
  4. Regular alcohol consumption in males> 21 units per week and Females > 14 units per week (1 Unit = 1/2 pint beer, 25 mL of 40or a 125 mL glass of wine)
  5. Subject has a borderline or long Fridericia interval as defined by screening readings of >430 msec for males and >440 for females or a personal or familial history of long QT syndrome
  6. Subject has participated in a clinical trial within 90 days prior to study initiation
  7. Females who are pregnant or breast feeding
  8. Subject has used any prescription medication or over-the-counter (OTC) medication, including vitamin supplements, within 21 days prior to day l
  9. Subject has been treated with any known P450 206 or 3A4 enzymes altering drugs within 30 days prior to the study
  10. Subject has smoked or used nicotine products within 2 months prior to or during the study
  11. Subject has sought advice from or been referred to a GP or counsellor for abuse or misuse of alcohol, non-medical drugs, medicinal drugs or other substance abuse, e.g. solvents
  12. Subject has a positive blood screen for , surface antigen (HBsAg), and Antibody
  13. Any current or previous use of drugs such as opiates, cocaine, ecstasy, or intravenous amphetamines and/or a positive urine screen for alcohol or drugs of abuse. Subjects who admit to occasional past use of cannabis will not be excluded as long as they have a negative drugs-of-abuse test and have been abstinent from cannabis use for at least 3 months
  14. Subject has a current uncontrolled inter-current illness (i.e., active infection) or has had a clinically significant illness within the last 30 days prior to Day 1
  15. Subject has had major surgery within 28 days of study entry, or 12 months prior to study for gastrointestinal surgery.
  16. Failure to satisfy the investigator of fitness to participate for any other reason.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Regimen A

    32 mg MIN-101 of the current modified-release formulation (comparator) identified as MR-32 formulation administered in the fasted state

    Drug: MIN-101

  • Experimental
    Regimen B

    32 mg MIN-101 MR administered in the fasted state

    Drug: MIN-101

  • Experimental
    Regimen C

    32 mg MIN-101 MR administered in the fasted state

    Drug: MIN-101

  • Experimental
    Part 2 selected dose

    32 mg MIN-101 of MR administered in the fed state

    Drug: MIN-101

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Plasma PK parameter, Cmax

    To estimate the relative bioavailability of MIN-l0l following MIN-101 administration. Plasma samples will be analyzed for MIN-101 and its metabolites using a validated LC-MS/MS method

    Time frame: from predose up to 72 hours post dose: Blood samples for MIN-101 will be collected at time 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 48, 60, and 72 hours post-dose on Day 1 of all periods.

  2. Part 1: Plasma PK parameter, Tmax

    Time frame: from predose up to 72 hours post dose

  3. Part 1: Plasma PK parameter, Tlag

    Time frame: from predose up to 72 hours post dose

  4. Part 1: Plasma PK parameter,partial AUC (e.g., AUC12, AUC24), AUClast, AUC∞

    Time frame: from predose up to 72 hours post dose

  5. Part 1: Plasma PK parameter, λz and t1/2

    Time frame: from predose up to 72 hours post dose

  6. Part 2: Plasma PK parameter, Cmax

    To estimate the relative bioavailability of MIN-101 and its main metabolites following the administration of the selected modified release formulation in different food conditions (fasted or fed state).

    Time frame: from predose up to 72 hours post dose: Blood samples for MIN-101 will be collected at time 0 (pre-dose), 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 24, 28, 32, 36, 48, 60, and 72 hours post-dose on Day 1 of all periods.

  7. Part 2: Plasma PK parameter, Tmax

    Time frame: from predose up to 72 hours post dose

  8. Part 2: Plasma PK parameter, Tlag

    Time frame: from predose up to 72 hours post dose

  9. Part 2: Plasma PK parameter, λz and t1/2

    Time frame: from predose up to 72 hours post dose

Secondary outcomes

  1. Part 1: QTcF changes from baseline

    The effect of coincidentally measured (time-matched) plasma concentrations of MIN-l0l on QTcF changes from Baseline.

    Time frame: from predose up to 72 hours post dose

  2. Part 1: Safety (AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments)

    Safety will be assessed through AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments

    Time frame: 2 months 16 days

  3. Part 2: Safety (AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments)

    Safety will be assessed through AE reporting, safety laboratory parameters analysis, vital signs and 12 lead ECG assessments

    Time frame: 2 months 16 days

07

Study locations

1 site
  • Biokinetic Europe
    Belfast, BT2 7BA, Ireland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2016 to primary completion in Apr 2017, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2017
First posted
Feb 1, 2017
StartActual
Nov 30, 2016
Primary completionActual
Apr 20, 2017
CompletionActual
Apr 20, 2017
Last update
Aug 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03038646
Lead sponsor
Minerva Neurosciences
Responsible party
Sponsor
First posted
Feb 1, 2017
Start date
Nov 30, 2016
Primary completion
Apr 20, 2017
Completion
Apr 20, 2017
Last update
Aug 31, 2017

Study contacts

Daniel Jabbari, MD
principal investigator · BioKinetic Europe Ltd

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roluperidone

Start the discussion